La tunisie Medicale - 2022 ; Vol 100 ( n°05 ) : 390-395
[ 300 times seen ]
Summary

Introduction and aim : Multidrug resistance in bacteria has become a widespread scourge. The objective of this study is to investigate the epidemiology of multidrug-resistant bacteria (MDR) at Fattouma Bourguiba University Hospital of Monastir - Tunisia compared to the community and to define their antibiotic resistance profiles.
Methods: It was a retrospective and descriptive study over a period of 5 years (2016-2020) conducted at the microbiology department of Fattouma-Bourguiba University Hospital of Monastir - Tunisia. All MDR strains isolated from diagnostic microbiological samples collected from patients hospitalized in high-risk infectious departments and from outpatients were included in our study.
Results : A total of 4324 MDR among 16353 bacteria were isolated during the study period, i.e. a resistance rate of 26.4% with a predominance of hospital strains (80.3% versus 19.7% in the city). Third generation cephalosporin-resistant Enterobacteriaceae were the most prevalent and were mainly represented by extended-spectrum beta- lactamases (67.1% versus 83.4% in the community). Escherichia coli was the most frequent species (40.9%). It was frequently associated with resistance to fluoroquinolones (in more than 73% of cases). Imipenem-resistant Acinetobacter baumannii was mostly responsible for hospital acquired infections (77%). Co- resistances concerned most of the antibiotics but spared colistin. Methicillin-resistant Staphylococcus aureus infections were more frequent in the city (20.5% versus 19.3% in hospitals). Resistance associated was mainly to fusidic acid (49.6%). Glycopeptides have maintained their activity and only 2% were of decreased sensitivity to vancomycin.
Conclusion : The emergence of MDR always represents a public health challenge. Thus, hygiene measures associated with an optimization of antibiotic therapy are necessary for a better control of their diffusion.

Key - Words
Article
Reference
  1. Friedrich AW. Control of hospital acquired infections and antimicrobial resistance in Europe: the way to go. Wien Med Wochenschr. 2019;169(S1):25‑30.
  2. Aslam B, Wang W, Arshad MI, Khurshid M, Muzammil S, Rasool MH, et al. Antibiotic resistance: a rundown of a global crisis. Infect Drug Resist. 2018;11:1645‑58.
  3. Vivas R, Barbosa AAT, Dolabela SS, Jain S. Multidrug-Resistant Bacteria and Alternative Methods to Control Them: An Overview. Microb Drug Resist. 2019;25(6):890‑908.
  4. Abat C, Fournier P-E, Jimeno M-T, Rolain J-M, Raoult D. Extremely and pandrug- resistant bacteria extra-deaths: myth or reality? Eur J Clin Microbiol Infect Dis. 2018;37(9):1687‑97.
  5. Medina E, Pieper DH. Tackling Threats and Future Problems of Multidrug- Resistant Bacteria. Curr Top Microbiol Immunol. 2016;398:3‑33.
  6. Neubeiser A, Bonsignore M, Tafelski S, Alefelder C, Schwegmann K, Rüden H, et al. Mortality attributable to hospital acquired infections with multidrug-resistant bacteria in a large group of German hospitals. J Infect Public Health. 2020;13(2):204‑10.
  7. Million Y, Feleke T, Mengesha D, Senay B, Tigabu A. MultidrugResistant Bacteria Among Culture Isolates at University of Gondar, Specialized Referral Hospital, Northwest Ethiopia: a Five-Year Retrospective Study. Clin Lab. 2020;66(7).
  8. Jia X-Q, Pang F, Chen J-Z, Jiang L-X. Prevalence and clinical distribution of multidrug-resistant bacteria (3537 isolates) in a tertiary Chinese hospital (January 2012–December 2013). Pathol Bio (Paris). 2015;63(1):21‑3.
  9. Majdoub A, Kalifa ABH, Bannour I, Meksi Y, Ouaz M, Kheder M. Epidemiological situation of Enterobacteriaceae resistant to cephalosporins third generation in the region of Mahdia, Tunisia (2002-2014). Tunis Med. 2018;96:7.
  10. Association Santé Publique. Résistance aux antibiotiques: Santé publique France Resources Page [Internet]. [updated 2022 March 29; cited 2022 June 23]. Available from: https://www. santepubliquefrance.fr / maladies-et-traumatismes/ infectionsassociees-aux-soins-et-resistance-aux antibiotiques /resistanceaux antibiotiques
  11. Amazian K, Fendri C, Missoum M, Noureddine B, Rahal K, Savey A, et al. Multicenter pilot survey of resistant bacteria in the Mediterranean area. Eur J Clin Microbiol Infect Dis. 2006;25:340‑3.
  12. Birgand G, Zahar J-R, Lucet J-C. Insight Into the Complex Epidemiology of Multidrug-Resistant Enterobacteriaceae. Clin Infect Dis. 2018;66(4):494‑6.
  13. Zahar J-R, Bille E, Schnell D, Lanternier F, Mechai F, Masse V,et al. Diffusion communautaire des entérobactéries sécrétrices de β-lactamase à spectre élargi (EBLSE). Med Sci (Paris). 2009;25(11):939‑44.
  14. Rohde AM, Zweigner J, Wiese-Posselt M, Schwab F, Behnke M, Kola A, et al. Incidence of infections due to third generation cephalosporin-resistant Enterobacteriaceae - a prospective multicentre cohort study in six German university hospitals. Antimicrob Resist Infect Control. 2018;7:159.
  15. Potz NAC, Hope R, Warner M, Johnson AP, Livermore DM, on behalf of the London & South East ESBL Project Group. Prevalence and mechanisms of cephalosporin resistance in Enterobacteriaceae in London and South-East England. J Antimicrob Chemother. 2006;58(2):320‑6.
  16. Ben Ammar S, Ben Mehidi M, Courcol R, Bouziane F, Boukhalfa S, Makhloufi M, et al. Résistance des entérobactéries aux carbapénèmes dans notre établissement (2014–2016). Med Mal Infect. 2017;47(4 Supplement):S29.
  17. Gales AC, Seifert H, Gur D, Castanheira M, Jones RN, Sader HS. Antimicrobial Susceptibility of Acinetobacter calcoaceticus– Acinetobacter baumannii Complex and Stenotrophomonas maltophilia Clinical Isolates: Results From the SENTRY Antimicrobial Surveillance Program (1997–2016). Open Forum Infect Dis. 2019;6(Supplement_1):S34‑46.
  18. Said D, Willrich N, Ayobami O, Noll I, Eckmanns T, Markwart R. The epidemiology of carbapenem resistance in Acinetobacter baumannii complex in Germany (2014– 2018): an analysis of data from the national Antimicrobial Resistance Surveillance system. Open Forum Infect Dis. 2021;10(1):45.
  19. Cattoen C, Levent T, Grandbastien B, Descamps D, Bouillet L, Coignard B, et al. Observatoire régional Pseudomonas aeruginosa du Nord-Pas-de-Calais : Données épidémiologiques et microbiologiques. Med Mal Infect. 1999;29(3):160‑6.
  20. Frikh M, A. Maleb INA. Pseudomonas aeruginosa : Epidémiologie et état actuel des résistances Etude retrospective sur trois ans. J Marocain Sci Med. 2017;21(2):34‑40.
  21. Barbier F, Wolff M. Multirésistance chez Pseudomonas aeruginosa : Vers l’impasse thérapeutique ? Med Sci (Paris). 2010;26(11):960‑8.
  22. Algammal A, Hetta HF, Elkelish A, Alkhalifah D, Hozzein W, Batiha G, and al. Methicillin-Resistant Staphylococcus aureus (MRSA): One Health Perspective Approach to the Bacterium Epidemiology, Virulence Factors, Antibiotic-Resistance, and Zoonotic Impact. Infect Drug Resist. 2020;13:3255‑65.
  23. Cristina Bellini, Nicolas Troilet. Résistance aux antibiotiques : état des lieux en Europe et en Suisse et impact pour le praticien. Rev Med Suisse. 2016;12:1699-702.
Login
E-mail :
Password :
Remember Me Forgot password? Sign UP
Archives
2022
January
February
March
April
May
June
July
August
September
October
November
December
Keywords most used
Tunisia treatment Child diagnosis surgery prognosis Children epidemiology Crohn’s disease Risk factors Breast cancer screening Cancer Ulcerative colitis obesity
Newsletter
Sign up to receive our newsletter
E-mail :
Stay in Touch
Join Us! !